News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Symyx Technologies, Inc. Rejects Certara Bid, Backs Accelrys Inc. Offer
June 21, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Scientific research provider Symyx Technologies Inc rejected a revised buyout proposal by Certara Corp, saying it was not superior to an offer made by Accelrys Inc earlier this year.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Mergers & acquisitions
Sanofi Buys Vigil for $470M Upfront, Reigniting a Battered Alzheimer’s Target
May 22, 2025
·
4 min read
·
Annalee Armstrong
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
May 21, 2025
·
2 min read
·
Heather McKenzie
Mergers & acquisitions
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
May 19, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
BioMarin Expands Enzyme Expertise With $270M Inozyme Buy
May 16, 2025
·
2 min read
·
Tristan Manalac
